SETUP

DOC is pressing against its 52-week high of $20.81, trading at $20.61 after a 31% rally from its 52-week low of $15.70. The MACD bullish cross on the daily confirms fresh momentum, and 13.32% outperformance versus SPY over 63 days signals institutional accumulation. The setup is a near-term breakout play targeting a decisive close above $20.81, which would establish new 52-week high territory with limited overhead resistance. Risk/reward of 1:1.51 is acceptable but not compelling given the proximity to the stop.

CATALYSTS

Healthpeak raised its 2026 FFOA outlook, a direct positive for valuation as REIT investors price on funds from operations. The Janus Living IPO monetization adds a balance sheet catalyst that was not in prior guidance. Macro tailwind: rate cut expectations continue to support REIT valuations broadly. Healthcare real estate demand remains structurally sound given aging demographics. Heavy cluster of insider buying on May 29 across CEO, CFO, CIO, and multiple officers is a strong internal vote of confidence.

RISKS

The stock is within 1% of its 52-week high and has already delivered a substantial run. A failure to break $20.81 on volume risks a double-top formation and rapid reversal back toward the mid-$19s. Earnings are erratic, with two significant misses in the last six quarters. The P/E of 64x on thin EPS of $0.32 leaves little margin for error. The reported dividend yield of 596% appears to be a data error and should be verified before sizing this as an income position. Beta near 1 means broad market weakness will drag DOC with it.

CONVICTION: Medium

The insider buying cluster and raised FFOA guidance are genuine positives, but the stock is stalling just under its 52-week high with a tight stop and inconsistent earnings history that limits confidence in follow-through.